Neurocognitive Dysfunction Oncology news and AP24534 Clinical Trials

[Guest guest]

PART I

Do cancer patients eperience impairments of neurocognitive function, including

memory loss, distractibility?

http://www.supportiveoncology.net/journal/articles/0603135.pdf dated January,

2008

_________________________________________________________________

PART II

AP24534 is currently being evaluated in a Phase 1 clinical study for the

treatment of patients with hematological (blood-based) cancers, and a second

Phase 1 study for the treatment of patients with solid tumors is planned to

begin in 2008.

In preclinical studies, AP24534 demonstrated efficacy and oral dosing

flexibility in animal models of chronic myeloid leukemia (CML), including forms

of CML caused by clinically relevant variants of the target protein, Bcr-Abl.

Specifically, AP24534 potently inhibited a specific mutant, T315I, which is

resistant to all currently available drugs. Additional preclinical studies

demonstrated that AP24534 also inhibits Flt3, a target associated with acute

myeloid leukemia (AML). http://www.ariad.com/wt/tertiarypage/kinase_inhibitors

Facts dated from 2007-2008

I tried to find the latest information on these subjects, note the current

dates.

Blessings and peace,

Lottie